KALV is no longer actively traded. Data shown reflects verified historical relationships.
2Suppliers
0Customers
3Debt Items
16Related Chains

KalVista Pharmaceuticals, Inc. Suppliers

TickerNameConfidenceEvidence
DRI-HEALTHCARE-ACQUISITIONS-LP DRI-HEALTHCARE-ACQUISITIONS-LP 90% Purchase Agreement by and between KalVista Pharmaceuticals, Inc. and DRI Healthcare Acquisitions LP, dated November 4, 2024.
DRI-UK-LP DRI-UK-LP 90% pursuant to which the Subsidiary sold to DRI the right to receive payments from the Subsidiary at a tiered percentage of future worldwide net sales of sebetralstat in exchange for an upfront payment …

KalVista Pharmaceuticals, Inc. Customers

No clients on recordNo downstream customers found in our database for KalVista Pharmaceuticals, Inc..

KalVista Pharmaceuticals, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
KALV-DEBT-10487 Warrants outstanding: 1853593 90% xbrl warrant detail from xbrl 2026-04-01.
KALV-DEBT-10488 Xbrl Convertible 90% xbrl convertible detail from xbrl 2015-12-31.
KALV-DEBT Debt stack $284.3M 90% Market cache reports total debt of $284.3M.

KalVista Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for KalVista Pharmaceuticals, Inc..

KalVista Pharmaceuticals, Inc. Ownership

HolderNameConfidenceEvidence
KALV-OWNER-VENROCK-ADVISER-LLC Venrock Adviser, LLC 90% 13F overlay lists Venrock Adviser, LLC as top holder; 185 tracked holders.

KalVista Pharmaceuticals, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CRBU Caribou Biosciences, Inc. 100.00 2
DTIL Precision BioSciences, Inc. 100.00 2
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
ALLO Allogene Therapeutics, Inc. 100.00 2
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
CLLS Cellectis S.A. 100.00 2
CELU Celularity Inc. 100.00 2
TKPHF Takeda Pharmaceutical Company Limited 100.00 2
MGX Metagenomi Therapeutics, Inc. 100.00 2
SGMO Sangamo Therapeutics, Inc. 100.00 2
IONS Ionis Pharmaceuticals, Inc. 100.00 2
KYTX Kyverna Therapeutics, Inc. 100.00 2
PRME Prime Medicine, Inc. 50.00 2
VRTX Vertex Pharmaceuticals Incorporated 50.00 2
RECODE RECODE 50.00 2
NTLA Intellia Therapeutics, Inc. 36.29 1 ['spend']